Support from Alzheimer’s Impact Movement (AIM) corporate champions enables AIM to undertake important additional work to end Alzheimer’s and all other dementia.

No contribution from any entity impacts AIM decision-making, nor our positions on issues related to people living with Alzheimer’s, other dementia and their families. Total contributions from the pharmaceutical industry makes 4.87% of AIM’s total contributed revenue.